Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more
Shandong Sito Bio-technology Co Ltd (300583) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.06 Billion CNY
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has total liabilities worth CN¥1.06 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shandong Sito Bio-technology Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shandong Sito Bio-technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Integrity Technology Co. Ltd. A
SHG:688244
|
China | CN¥125.22 Million |
|
Dye & Durham Limited
PINK:DYNDF
|
USA | $1.84 Billion |
|
Pss Co Ltd
TW:6914
|
Taiwan | NT$6.86 Billion |
|
Chongqing Changjiang River Moulding Material (Group) Co. Ltd.
SHE:001296
|
China | CN¥419.36 Million |
|
Wistron Information Technology & Services
TWO:4953
|
Taiwan | NT$1.77 Billion |
|
RGC Resources Inc
NASDAQ:RGCO
|
USA | $224.61 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Shandong Sito Bio-technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Sito Bio-technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shandong Sito Bio-technology Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.14 Billion | -2.82% |
| 2023-12-31 | CN¥1.17 Billion | -4.04% |
| 2022-12-31 | CN¥1.22 Billion | -1.09% |
| 2021-12-31 | CN¥1.24 Billion | +7.63% |
| 2020-12-31 | CN¥1.15 Billion | +4.49% |
| 2019-12-31 | CN¥1.10 Billion | +50.21% |
| 2018-12-31 | CN¥732.63 Million | +130.81% |
| 2017-12-31 | CN¥317.42 Million | -4.74% |
| 2016-12-31 | CN¥333.22 Million | +0.48% |
| 2015-12-31 | CN¥331.62 Million | +53.30% |
| 2014-12-31 | CN¥216.31 Million | +93.44% |
| 2013-12-31 | CN¥111.83 Million | +306.45% |
| 2012-12-31 | CN¥27.51 Million | -- |